Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01969643 (Clinical Trial / SGN-LIV1A)

Study Title
A Safety Study of SGN-LIV1A in Breast Cancer Patients (NCT01969643)

Trial Description
This study is being conducted to examine the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer, and to find the highest dose of the drug that can be given without unacceptable side effects. Other goals of the trial are to find out if SGN-LIV1A has any antitumor effects, to learn about the pharmacokinetics of SGN-LIV1A, and to explore the relationship between antigen expression and SGN-LIV1A effects.

This trial is sponsored by Seattle Genetics. [1]

Study Data

  • Condition: Breast Cancer
  • Interventions:
    • Drugs used in this trial
      • SGN-LIV1A
  • Phase: I
  • Estimated Enrollment: 216
  • Start: September 2013
  • Estimated Completion: December 2019
  • Last verified: February 2018

Study Schematic

NCT01969643

Click here to Return to Drug map


Last Editorial review: February 2018
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2018 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar